Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551943 | 1.00 | MAPT (0.50) | MAPTALDH1A1MAPK1POLBCYP2C9 | |
| SCHEMBL17994179 | 0.93 | MAPT (0.55) | MAPTALDH1A1MAPK1POLBCYP2C9 | |
| SCHEMBL16398474 | 0.84 | MAPT (0.51) | MAPTALDH1A1MAPK1POLBSMN1; SMN2 | |
| SCHEMBL16398478 | 0.84 | MAPT (0.51) | MAPTALDH1A1MAPK1POLBSMN1; SMN2 | |
| SCHEMBL1749643 | 0.84 | MAPT (0.53) | MAPTALDH1A1MAPK1POLBCYP2C9 | |
| SCHEMBL1749642 | 0.84 | MAPT (0.53) | MAPTALDH1A1MAPK1POLBCYP2C9 | |
| SCHEMBL1534427 | 0.83 | NOTUM (0.55) | — | |
| SCHEMBL3547081 | 0.82 | ALDH1A1 (0.50) | MAPTALDH1A1POLBLMNAKMT2A | |
| SCHEMBL1025469 | 0.82 | HTT (0.46) | MAPTALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL1025470 | 0.82 | HTT (0.46) | MAPTALDH1A1CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | MAPT 3632/4885ALDH1A1 320/4885MAPK1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.